Cargando…
Challenges of Integrating Biosimilars Into Clinical Practice
Presenters at JADPRO Live 2019 discussed the chemical and clinical nature of biosimilars, reviewed biosimilar development in oncology, and discussed implementation strategies for biosimilars.
Autores principales: | Jeffers, Kate, May, Megan, Vogel, Wendy H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857316/ https://www.ncbi.nlm.nih.gov/pubmed/33598319 http://dx.doi.org/10.6004/jadpro.2020.11.3.6 |
Ejemplares similares
-
Practical Considerations for Integrating Biosimilars Into Clinical Practice
por: May, Megan B., et al.
Publicado: (2021) -
Current status and considerations on biosimilar in China
por: Wang, Junzhi
Publicado: (2012) -
Integromics: challenges in data integration
por: Venkatesh, TV, et al.
Publicado: (2002) -
Integrating Biosimilars Into Oncology Practice: Implications for the Advanced Practitioner
por: Campen, Christopher J.
Publicado: (2017) -
Antibody biosimilars: Fears or opportunities?: First LabEx MAbImprove industrial workshop, May 28, 2013; Tours, France
por: Guillon-Munos, Audrey, et al.
Publicado: (2014)